Skip to main content
SpringerLink
Log in

Asthma bronchiale — personalisierte Therapie am Horizont?

  • Übersicht
  • Published:
Allergo Journal Aims and scope Submit manuscript

Abstract

In den letzten Jahren ist eine deutliche Entwicklung in der Medizin hin zu personalisierten Therapieansätzen zu beobachten. Auch bei der Behandlung des Asthma bronchiale sind in den letzten Jahren erhebliche Fortschritte in unserem Verständnis der Erkrankung erzielt worden. Dieses scheint nun auch in spezifische Therapieansätze zu resultieren, die nicht für alle Patienten sondern nur für eine spezifische Gruppe eingesetzt werden. Dazu gehören neben dem bereits zugelassenen anti-IgE auch neue Antikörper so wie anti-IL-5 und anti-IL-13. Für welche Patientengruppen diese am besten eingesetzt werden können ist zur Zeit Stand der Forschung.

Zitierweise: Taube C. Bronchial Asthma: is personalized therapy on the horizon? Allergo J Int 2014; 23:246–51 DOI: 10.1007/s40629-014-0028-y

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Abbreviations

ATS:

American Thoracic Society

ERS:

European Respiratory Society

HES:

Hypereosinophiles Syndrom

ICS:

Inhalative Kortikoseroide

IgE:

Immunglobulin E

IL:

Interleukin

IL-4Rα:

IL-4-Rezeptor α

LABA:

Langwirksame β-Mimetika

NO:

Stickstoffmonoxid

OX40L:

OX40-Ligand

Th:

T-Helferzellen

TSLP:

Thymic stromal lymphopoietin

Literatur

  1. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650–8

    Article  CAS  PubMed  Google Scholar 

  2. Taube C, Buhl R. [Does phenotyping asthma help to improve differential treatment?]. Dtsch Med Wochenschr 2010;135:468–73

    Article  CAS  PubMed  Google Scholar 

  3. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355–60

    Article  PubMed  Google Scholar 

  4. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:673–83

    Article  CAS  PubMed  Google Scholar 

  5. Taube C, Dakhama A, Gelfand EW. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 2004;135:173–86

    Article  PubMed  Google Scholar 

  6. Horn BR, Robin ED, Theodore J, Van KA. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975;292:1152–5

    Article  CAS  PubMed  Google Scholar 

  7. Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol 1981;75:693–700

    CAS  PubMed  Google Scholar 

  8. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013;132:821–7

    Article  CAS  PubMed  Google Scholar 

  9. Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007;119:1043–52

    Article  CAS  PubMed  Google Scholar 

  10. Korn S, Taube C, Buhl R. [Treatment strategies for asthma]. Internist 2012;53:429–38

    Article  CAS  PubMed  Google Scholar 

  11. Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol 2011;107:474–9

    Article  PubMed  Google Scholar 

  12. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–73

    Article  CAS  PubMed  Google Scholar 

  13. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725–31

    Article  CAS  PubMed  Google Scholar 

  14. Braunstahl GJ, Chlumsky J, Peachey G, Chen CW. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 2013;9:47

    Article  PubMed Central  PubMed  Google Scholar 

  15. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64:1728–36

    Article  CAS  PubMed  Google Scholar 

  16. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005–15

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573–82

    Article  PubMed  Google Scholar 

  18. Schreiber J, Kopp MV, Korn S, Taube C, Buhl R. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma]. Pneumologie 2014;68:187–92

    Article  CAS  PubMed  Google Scholar 

  19. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et al. A proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. Chest 2013;144:411–9

    Article  CAS  PubMed  Google Scholar 

  20. Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax 2014;69:94–6

    Article  PubMed Central  PubMed  Google Scholar 

  21. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215–28

    Article  CAS  PubMed  Google Scholar 

  22. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–84

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–93

    Article  CAS  PubMed  Google Scholar 

  24. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–9

    Article  CAS  PubMed  Google Scholar 

  25. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125–32

    Article  CAS  PubMed  Google Scholar 

  26. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132:1086–96

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. O’Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol 2011;128:257–63

    Article  PubMed  Google Scholar 

  28. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–98

    Article  CAS  PubMed  Google Scholar 

  29. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW et al. The role of IL-13 in established allergic airway disease. J Immunol 2002;169:6482–9

    Article  CAS  PubMed  Google Scholar 

  30. McKenzie AN, Fallon PG. Decoy receptors in the regulation of T helper cell type 2 responses. J Exp Med 2003;197:675–9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–66

    Article  CAS  PubMed  Google Scholar 

  32. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130–9

    Article  PubMed  Google Scholar 

  33. Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014;44:29–37

    Article  CAS  PubMed  Google Scholar 

  34. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218–24

    Article  PubMed Central  PubMed  Google Scholar 

  35. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322–9

    Article  PubMed  Google Scholar 

  36. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294–302

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, Niederlande

    Christian Taube MD

Authors
  1. Christian Taube MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Taube MD.

Additional information

Interessenkonflikt

Der Autor hat Vergütungen für Vorträge und/oder Advisory Boards von Boehringer Ingelheim, Novartis, Almirall, AstraZeneca, Chiesi und GlaxoSmith Kline erhalten.

Zitierweise

Taube C. Bronchial asthma: is personalized therapy on the horizon? Allergo J Int 2014;23:246–51 DOI: 10.1007/s40629-014-0028-y

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taube, C. Asthma bronchiale — personalisierte Therapie am Horizont?. Allergo J 23, 18–23 (2014). https://doi.org/10.1007/s15007-014-0679-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-014-0679-5

Schlüsselwörter

Search

Navigation